MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, is in preclinical development advancing mesencephalic astrocyte-derived neurotrophic factor (MANF) as a disease-modifying treatment for orphan ophthalmological conditions and neurodegenerative diseases. On Tuesday, the company announced it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) covering the use of MANF or cerebral dopamine neurotrophic factor (CDNF) as a treatment for various disorders, including glaucoma, macular degeneration and retinitis pigmentosa. The approved claims cover the use of MANF or CDNF administered as an eye drop or by intravitreal injection. MANF Therapeutics is focused on the advancement of MANF for multiple therapeutic indications.
MANF has significant therapeutic potential across multiple orphan ophthalmological conditions such as RAO, and retinitis pigmentosa, where MANF has already received orphan drug designations from the FDA, Wolfram’s Syndrome, as well as in larger indications such as glaucoma, Parkinson’s disease, diabetes and cardiovascular disease, including stroke and myocardial infarction. MANF Therapeutics is the front-runner and primary worldwide intellectual property (IP) holder for MANF-based therapies including protein therapy, gene therapy and cell therapy. The company owns rights to composition of matter patents and patent applications for MANF and owns, or has licenses to, method of use patents and patent applications covering the use of MANF in ophthalmology, neurology and diabetes.